口服蛋白质和多肽市场（按产品类型、配方、药物开发阶段、应用和最终用户划分）—2025-2032 年全球预测

预计到 2032 年，口服蛋白质和胜肽市场将成长至 192.1 亿美元，复合年增长率为 13.67%。

全面介绍口服蛋白质和胜肽疗法如何重新定义整个医疗保健系统的临床交付模式和商业策略

蛋白质和多肽的口服给药代表着治疗方法的关键性变革，它重塑了临床医生、患者和行业相关人员对生物製剂治疗途径的认知。最近的技术进步解决了酶降解、上皮渗透性和生物有效性度缺乏一致性等障碍，将曾经只能注射的分子转变为口服给药的候选药物。因此，研发人员正在探索各种配方策略和给药平台，将化学、设备工程和製剂科学结合，以探索患者偏好的给药途径，并扩大生技药品的治疗范围。

随着监管格局的日趋成熟，监管机构和支付方越来越关注口服蛋白质和多肽为慢性病管理、癌症支持治疗和荷尔蒙疗法提案的差异化价值主张。这种转变正在影响投资重点、合作策略和临床开发路径。重要的是，临床和商业性潜力不仅取决于分子创新，还取决于可扩展的生产、检验的药物动力学性能以及可重复的真实世界依从性结果。这些因素共同构成了一个复杂的生态系统，其中科学前景和商业性可行性必须协调一致。

本执行摘要融合了策略曲折点、细分市场驱动的洞察、区域动态、公司指南和可操作性建议，旨在指导领导者在产品线优先顺序、通路开发和製造布局方面做出具有时效性的决策。本分析着重于可操作性情报和严谨方法的透明度，旨在帮助相关人员应对复杂的监管环境、优化产品系列，并加速病患在不同医疗环境中的可及性。

极具影响力的科学、监管和商业性曲折点，加速从注射生技药品到患者首选口服製剂的转变

在科学、监管和商业性力量融合的推动下，口服蛋白质和胜肽的市场格局正在经历一系列变化。首先，吸收促进剂、蛋白酶抑制剂和载体技术的进步显着提高了某些胜肽类的口服生物有效性，使得先前仅限于肠外给药的分子能够重新配製用于口服给药。肠溶衣和奈米颗粒系统以及製剂化学的进步提高了胃肠道稳定性，使长期口服方案更加可行。

同时，法律规范也在不断发展，以适应新型治疗方法和组合药物。监管机构正在明确生物等效性、安全边际以及器械-药物联合开发的证明途径，以减少申办方的不确定性，并透过更早的协调加快开发进度，尤其是在口服给药已被证明可以提高依从性、减少就诊次数并减少注射相关不利事件的情况下。

商业性，相关人员的期望也在改变。患者和医疗保健提供者越来越重视便利性和生活质量，而医疗系统则严格审查医疗保健总成本。这些趋势正在推动专业生物技术公司、合约开发和受託製造厂商以及更广泛的製药生态系统之间建立策略伙伴关係，以整合临床开发、可扩展製造和全球分销方面的能力。最后，再形成，而有效的患者援助计划和渠道策略将决定最终的赢家和市场动态。

2025 年实施的贸易政策转变如何推动整个口服生技药品价值链的供应链重组、采购多元化和战略协议

2025年生效的贸易政策调整，为口服蛋白质和多肽製造商和经销商带来了新的营运和策略复杂性。关税变化改变了关键投入品的到岸成本，包括辅料、先进配方成分和特殊包装材料。因此，筹资策略已转向优先考虑供应商多元化和区域采购，以减少单一国家关税的影响，并缓解投入品价格波动。

製造商的应对之策是重新评估其全球製造布局，并加速关于近岸外包和多站点冗余的讨论。这些决策不仅出于成本考虑，还考虑到前置作业时间的可靠性、跨辖区监管的协调性以及持续供应慢性病药物的需求。随着企业寻求在不加剧贸易摩擦的情况下实现跨地区灵活的生产能力，对受託製造厂商的需求再次上升。

同时，关税环境也影响了伙伴关係结构和商业合约。企业越来越多地将关税应急条款纳入供应商合约和定价模型，一些企业也采取了对冲策略，以保护利润免受短期贸易中断的影响。付款人和综合医疗服务网络也重新调整了采购预期，预测潜在的传导效应，并寻求风险分担安排，以稳定病患的就医管道。

重要的是，关税加速了对原料标准化和製程优化的投资，从而降低了单剂量成本并增强了供应链的韧性。一些企业也重新平衡了研发预算，优先考虑製程改善和配方稳健性，从而减少了对稀缺或关税敏感型投入的依赖。整体而言，2025年关税的累积影响促使企业采取策略性倡议，转向供应链敏捷性、协同製造模式和合约结构，旨在在更不确定的贸易环境中保持市场进入和价格稳定。

细分主导框架，将产品类型、配方选择、临床开发阶段、治疗用途和最终用户管道与策略决策连结起来

深入的细分揭示了科学进步与商业性机会的交汇点，使领导者能够根据患者需求和可行性调整投资和开发重点。根据产品类型，市场分为基于胰岛素的蛋白质和胜肽疗法。基于胰岛素的蛋白质类别包括复合胰岛素、长效胰岛素类似物、速效胰岛素类似物和重组人类胰岛素，每种类型都面临与酵素稳定性和吸收动力学相关的独特配方和给药挑战。胜肽类疗法类别包括基于抑钙素的疗法、Glucagon-Like Peptide-1受体促效剂和加压素类似物，其中分子大小、受体药理学和目标适应症决定了口服给药的可行性。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 脂质化和聚乙二醇化技术的进步可提高口服胜肽的稳定性和生物有效性
• 整合下一代渗透促进剂以增强口服蛋白质药物的细胞渗透
• 糖尿病治疗中口服胰岛素和GLP-1类似物的自乳化药物传递系统的开发
• 在配方中使用新型蛋白酶抑制剂来保护治疗性胜肽免于消化降解
• 针对微生物组的胜肽疗法调节肠道菌丛并提高口服药物疗效的新用途
• 生技公司与製药公司之间的策略合作，加速口服胜肽疫苗和疗法的商业化
• 美国和欧盟监管协调努力简化口服胜肽类候选药物的核准途径
• 应用人工智慧驱动的胜肽工程平台优化口服生物有效性并缩短开发时间

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 口服蛋白质和胜肽市场（依产品类型）

• 胰岛素类蛋白质
  • 结合胰岛素製剂
  • 长效胰岛素类似物
  • 速效胰岛素类似物
  • 重组人类胰岛素
• 胜肽疗法
  • 以抑钙素为基础的治疗方法
  • Glucagon-Like Peptide-1受体促效剂
  • 加压素类似物

9. 口服蛋白质和多胜肽市场（按配方）

• 胶囊剂型
• 液体製剂
• 粉末製剂
• 片剂配方

第 10 章：口服蛋白质和多胜肽市场（依药物开发阶段）

• I期和II期临床试验
• III期临床试验
• 上市后监测
• 临床前研究

第11章口服蛋白质和多肽市场（按应用）

• 癌症治疗
• 心血管疾病
• 糖尿病管理
• 荷尔蒙失调

第 12 章：口服蛋白质和胜肽市场（按最终用户）

• 居家照护环境
• 医院和诊所
• 实验室
• 专科诊所

13. 口服蛋白质和多肽市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章口服蛋白质和多肽市场（按类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第 15 章。按国家/地区分類的口服蛋白质和胜肽市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • AbbVie Inc.
  • Amgen Inc.
  • Amryt Pharma plc
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • Entera Bio Ltd. by DNA Biomedical Solutions
  • F. Hoffmann-La Roche AG
  • Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • PeptiDream Inc.
  • Pfizer, Inc.
  • Protagonist Therapeutics, Inc.
  • Proxima Concepts Limited
  • Rani Therapeutics, LLC
  • Sanofi SA
  • Tarsa Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Zealand Pharma A/S

The Oral Proteins & Peptides Market is projected to grow by USD 19.21 billion at a CAGR of 13.67% by 2032.

A comprehensive orientation to how oral protein and peptide therapeutics are redefining clinical delivery models and commercial strategies across healthcare systems

Oral delivery of proteins and peptides represents a pivotal evolution in therapeutic modalities, reshaping how clinicians, patients, and industry stakeholders conceive of biologic treatment pathways. Recent technological advances have transformed molecules that were once strictly injectable into candidates for oral administration by addressing barriers such as enzymatic degradation, epithelial permeability, and inconsistent bioavailability. Consequently, developers have pursued a range of formulation strategies and delivery platforms that converge across chemistry, device engineering, and formulation science to unlock patient-preferred routes of administration and broaden the therapeutic footprint of biologics.

As the landscape matures, regulatory authorities and payers are increasingly attuned to the differentiated value propositions that oral proteins and peptides bring to chronic disease management, oncology supportive care, and hormonal therapies. This shift influences investment priorities, partnership strategies, and clinical development pathways. Importantly, the clinical and commercial potential hinges not only on molecular innovation but also on scalable manufacturing, validated pharmacokinetic performance, and reproducible real-world adherence outcomes. Taken together, these elements define a complex ecosystem in which scientific promise must align with commercial feasibility.

This executive summary synthesizes strategic inflection points, segmentation-driven insights, regional dynamics, corporate approaches, and pragmatic recommendations to guide leaders who must make time-sensitive decisions about pipeline prioritization, channel development, and manufacturing footprints. By focusing on actionable intelligence and rigorous methodological transparency, the analysis supports stakeholders seeking to navigate regulatory complexity, optimize product portfolios, and accelerate patient access across diverse care settings.

High-impact scientific, regulatory, and commercial inflection points that are accelerating the transition of injectable biologics to patient-preferred oral formats

The landscape for orally delivered proteins and peptides is undergoing a set of transformative shifts driven by converging scientific, regulatory, and commercial forces. First, advances in absorption enhancers, protease inhibitors, and carrier technologies have materially improved oral bioavailability for select peptide classes, enabling molecules previously constrained to parenteral routes to be reimagined for oral dosing. Alongside formulation chemistry, progress in enteric coatings and nanoparticulate systems has enhanced stability through the gastrointestinal tract, thereby increasing the feasibility of chronic oral regimens.

Simultaneously, regulatory frameworks are evolving to accommodate novel modalities and combination products. Regulatory agencies are clarifying pathways for demonstrating bioequivalence, safety margins, and device-drug co-development, which reduces uncertainty for sponsors and accelerates development timelines when aligned early. Payer conversations are also intensifying around the long-term value delivered by oral biologics, particularly when oral dosing demonstrably improves adherence, reduces clinic visits, and mitigates injection-related adverse events.

Commercially, stakeholder expectations are shifting. Patients and providers increasingly prioritize convenience and quality of life, while health systems scrutinize total cost of care. These drivers incentivize strategic partnerships between specialty biotechnology firms, contract development and manufacturing organizations, and the larger pharmaceutical ecosystem to bridge capabilities in clinical development, scalable manufacturing, and global distribution. Finally, the competitive landscape is being reshaped by the emergence of oral formulations targeting chronic indications, where the potential for broad uptake is high and where effective patient support programs and channel strategies will determine winner-take-share dynamics.

How trade policy shifts implemented in 2025 catalyzed supply chain reconfiguration, sourcing diversification, and strategic contracting across the oral biologics value chain

Trade policy adjustments enacted in 2025 introduced a new layer of operational and strategic complexity for manufacturers and distributors engaged in oral proteins and peptides. Tariff changes altered landed costs across critical inputs including excipients, advanced formulation components, and specialized packaging materials. As a consequence, procurement strategies shifted to prioritize supplier diversification and regional sourcing to reduce exposure to single-country tariffs and mitigate volatility in input pricing.

Manufacturers responded by reassessing global manufacturing footprints and accelerating conversations about nearshoring and multi-site redundancy. These decisions were influenced not only by cost considerations but also by lead-time reliability, regulatory harmonization across jurisdictions, and the need to preserve uninterrupted supply for chronic therapies. Contract manufacturing organizations experienced renewed demand as companies sought flexible capacity that could be deployed across geographies without triggering additional trade frictions.

In parallel, the tariff environment influenced partnership structures and commercial contracting. Organizations increasingly embedded tariff contingencies into supplier contracts and pricing models, and some adopted hedging strategies that insulated margins from short-term trade disruptions. Payers and integrated delivery networks also recalibrated procurement expectations, anticipating potential price pass-through effects and seeking risk-sharing arrangements that stabilized access for patients.

Importantly, the tariffs accelerated investment in component standardization and process optimization to reduce cost per dose and strengthen supply chain resilience. R&D budgets were rebalanced in some organizations to prioritize process intensification and formulation robustness, thereby reducing dependence on scarce or tariff-sensitive inputs. Overall, the cumulative impact of tariff policy in 2025 catalyzed strategic moves toward supply chain agility, collaborative manufacturing models, and contract structures designed to preserve market access and pricing stability in a more uncertain trade environment.

A segmentation-driven framework that connects product types, formulation choices, clinical development stages, therapeutic applications, and end-user channels to strategic decision-making

Insightful segmentation illuminates where scientific advances and commercial opportunities intersect, enabling leaders to align investments and development priorities with patient needs and canal feasibility. Based on product type, the market divides into insulin-based proteins and peptide therapeutics. The insulin-based proteins category includes combination insulin products, long-acting insulin analogues, rapid-acting insulin analogues, and recombinant human insulin, each presenting distinct formulation and delivery challenges tied to enzymatic stability and absorption kinetics. The peptide therapeutics category encompasses calcitonin-based therapies, glucagon-like peptide-1 receptor agonists, and vasopressin analogs, where molecular size, receptor pharmacology, and target indication shape feasibility for oral administration.

Based on formulation, the market spans capsule formulations, liquid formulations, powder formulations, and tablet formulations, and each format imposes trade-offs between stability, dose uniformity, manufacturability, and patient convenience. Developers must evaluate these trade-offs in the context of intended dosing frequency, target population, and distribution model. Based on development stage, the market includes Phase I & II clinical trials, Phase III clinical trials, post-market surveillance, and preclinical studies, reflecting a continuum where translational hurdles at early stages can materially affect later-stage commercialization pathways and risk profiles.

Based on application, the market targets cancer treatment, cardiovascular diseases, diabetes management, and hormonal disorders, with each therapeutic area presenting unique regulatory expectations, clinical endpoints, and payer evidence requirements. Developers should tailor clinical programs and value dossiers to the specific evidentiary demands of these indications. Based on end-user, the market serves home care settings, hospitals and clinics, research laboratories, and specialty clinics, which influences distribution strategies, patient support programs, and device design considerations to ensure adherence and patient safety outside traditional clinical settings.

Integrating segmentation perspectives highlights that portfolio decisions cannot be made in isolation; product type dictates formulation feasibility, while development stage dictates evidentiary requirements and time to access. Applications determine payer dialogue and clinical endpoint selection, and end-user considerations drive packaging, patient support, and distribution models. Leaders must therefore apply segmentation-driven lenses to align R&D, manufacturing, regulatory, and commercial teams toward coherent product strategies.

Strategic regional dynamics and go-to-market nuances across the Americas, Europe Middle East and Africa, and Asia-Pacific that determine access and scale for oral biologics

Regional dynamics shape the clinical trial landscape, manufacturing priorities, regulatory interactions, and commercialization strategies for oral proteins and peptides, and understanding these contours is essential for effective market entry. In the Americas, innovation hubs and integrated health systems create fertile conditions for early adoption of patient-centric delivery models, while established regulatory pathways offer predictable interactions but also require comprehensive real-world evidence to support broad reimbursement. As a result, companies often pilot adherence programs and value-based contracting frameworks in this region to demonstrate downstream cost offsets and improved outcomes.

In Europe, Middle East & Africa, heterogeneous regulatory environments and varied payer architectures necessitate differentiated market access strategies. This region demands adaptive regulatory engagement, selective country launches informed by local clinical practice patterns, and partnership approaches that leverage regional manufacturing or distribution partners to navigate importation and reimbursement complexity. Moreover, public health priorities and procurement frameworks can accelerate uptake in settings where oral delivery reduces clinic burden and supports decentralized care.

In the Asia-Pacific region, rapid adoption of novel therapeutics, strong manufacturing capacity, and growing local biotech ecosystems make it an important theater for both clinical development and scaled manufacturing. Regulatory authorities across the region are increasingly open to innovative trial designs and collaborative review processes, yet local market dynamics such as pricing pressure and competitive generics markets influence commercialization tactics. Consequently, strategic entry often combines clinical partnerships, local manufacturing or tolling arrangements, and tailored patient support programs that reflect regional care delivery models and payer expectations.

Collectively, regional insights underscore the need for geographically nuanced strategies that balance global regulatory alignment with local commercialization realities. Organizations that tailor their clinical programs, supply chain architecture, and reimbursement engagement to the specific characteristics of each region will be better positioned to convert clinical innovation into sustained patient access.

How corporate strategies, partnerships, and operational choices are aligning to derisk development and accelerate commercialization of oral peptide and protein therapeutics

Companies operating in the oral proteins and peptides domain are pursuing diverse strategies to de-risk development and accelerate commercialization. Some firms concentrate on proprietary formulation platforms that enable oral bioavailability across multiple peptide classes and therefore pursue licensing and platform partnerships to monetize their technology. Others prioritize tight integration of clinical and manufacturing capabilities to ensure a seamless path from early-phase demonstration of pharmacokinetics to scale-up for commercial production. Across the ecosystem, collaboration with contract development and manufacturing organizations has emerged as a common strategy to secure flexible capacity without incurring large capital expenditures.

Strategic alliances extend beyond manufacturing to include distribution partners, specialty pharmacies, and digital therapeutics vendors that can bolster adherence and real-world monitoring. Companies are also investing in evidence generation that aligns with payer value frameworks, including longitudinal adherence studies, health economics analyses, and comparator trials that highlight differential benefits of oral administration. In parallel, some organizations direct resources to improving supply chain resilience through multi-sourcing strategies and qualification of alternate excipient suppliers to mitigate disruption risk.

R&D pipelines reflect a spectrum of focus areas, from insulin analogues repurposed for oral dosing to peptide receptor agonists aimed at chronic metabolic and cardiovascular indications. Firms that pair robust clinical development programs with early payer engagement and clear manufacturing scale plans tend to accelerate path-to-reimbursement and market uptake. Finally, leadership teams are increasingly emphasizing regulatory foresight, embedding regulatory science expertise early in development to navigate combination product pathways, bioavailability challenges, and post-market surveillance obligations that accompany novel oral biologic formulations.

Actionable strategic priorities and operational levers that leaders must implement to convert oral biologic innovation into enduring commercial success

Industry leaders should prioritize a set of actionable steps that convert technical promise into sustainable commercial performance. First, integrate formulation and device development with early clinical trial design to ensure that pharmacokinetic and adherence objectives are embedded into pivotal study endpoints. This alignment reduces development iterations and improves the evidentiary continuity payers expect when assessing comparative value. Second, institutionalize supply chain resilience through supplier diversification, qualification of regional manufacturing partners, and modular production strategies that allow capacity redeployment as market demand evolves.

Third, begin payer and health system engagement early, using real-world demonstration projects to quantify adherence benefits and downstream resource offsets attributable to oral delivery. Early value conversations will smooth market access pathways and inform pricing strategies that reflect total cost of care. Fourth, structure partnerships that complement internal capabilities rather than duplicate them; selective licensing of platform technologies or co-development arrangements with established formulation specialists can accelerate timelines while preserving strategic control over core assets.

Fifth, invest in post-market evidence platforms that capture adherence, patient-reported outcomes, and pharmacovigilance data in decentralized settings. Such investments will support regulatory commitments and enrich the value proposition presented to payers and providers. Finally, adopt a staged regional deployment strategy that sequences launches to balance regulatory complexity, manufacturing capacity, and commercial readiness, thereby protecting margins while maximizing learnings for subsequent market entries.

A transparent mixed-methods research approach combining expert interviews, cross-functional workshops, and scenario analysis to ensure actionable and defensible insights

This analysis synthesizes primary and secondary research conducted under rigorous methodological standards to ensure reproducibility and strategic relevance. The research approach combined structured interviews with subject matter experts across formulation science, clinical development, regulatory affairs, manufacturing, and commercial operations. These qualitative insights were triangulated with publicly available regulatory guidance, peer-reviewed literature, and company disclosures to validate technical claims and infer likely industry responses to policy shifts.

Analytical methods included cross-functional workshops to map value chain dependencies, scenario planning to assess the impact of trade and regulatory volatility, and comparative case analyses of oral formulation programs across therapeutic areas. Where appropriate, assumptions were stress-tested through sensitivity analyses focused on key development and supply chain variables such as formulation success probability, manufacturing lead times, and post-approval surveillance requirements. The study also incorporated a limitations section that explicitly acknowledges areas of residual uncertainty, including long-term adherence behavior in real-world settings and evolving regulatory interpretations for novel delivery technologies.

Ethical protocols guided all primary research, ensuring informed consent, confidentiality, and the anonymization of proprietary insights. Finally, findings were peer-reviewed internally by multidisciplinary experts to ensure analytic rigor and practical applicability for stakeholders considering investments, partnerships, or portfolio reprioritization in oral proteins and peptides.

Concise synthesis of why integrated scientific, operational, and commercial alignment is essential for realizing the clinical and economic promise of oral biologic therapies

Oral proteins and peptides are moving from conceptual promise toward tangible clinical and commercial reality, propelled by advances in formulation science, shifting regulatory clarity, and evolving patient and payer expectations. These dynamics create a fertile environment for innovation but also impose new demands on organizational agility, supply chain design, and evidence generation. Success will favor organizations that integrate cross-disciplinary expertise early, structure partnerships to fill capability gaps, and align development strategies with pragmatic market access planning.

The interplay between product type, formulation path, development stage, application area, and end-user setting underscores the importance of segmentation-aware decision-making. Regional nuances further compel tailored strategies that balance global ambitions with local operational readiness. Importantly, recent trade policy adjustments have underscored the fragility of input-dependent value chains, accelerating moves toward diversified sourcing and regional capacity.

In sum, stakeholders who adopt an integrated approach-one that synchronizes scientific validation, manufacturing scalability, regulatory foresight, and payer-focused evidence development-will be best positioned to translate oral biologic advances into improved patient outcomes and durable commercial performance. The imperative now is to act with speed, precision, and collaborative intent to capture the window of opportunity that this therapeutic evolution presents.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Advancements in lipidation and PEGylation techniques to enhance oral peptide stability and bioavailability
• 5.2. Integration of next generation permeation enhancers to facilitate transcellular transport of oral protein drugs
• 5.3. Development of self-emulsifying drug delivery systems for oral insulin and GLP-1 analogues in diabetic therapy
• 5.4. Adoption of novel protease inhibitors in formulation design to protect therapeutic peptides from gastrointestinal degradation
• 5.5. Emerging use of microbiome-targeted peptide therapeutics to modulate gut flora and improve oral drug efficacy
• 5.6. Strategic partnerships between biotech and pharmaceutical firms to accelerate commercialization of oral peptide vaccines and therapies
• 5.7. Regulatory harmonization efforts in the US and EU driving streamlined approval pathways for oral peptide drug candidates
• 5.8. Application of AI-driven peptide engineering platforms to optimize oral bioavailability and reduce development timelines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Proteins & Peptides Market, by Product Type

• 8.1. Insulin-Based Proteins
  • 8.1.1. Combination Insulin Products
  • 8.1.2. Long-Acting Insulin Analogues
  • 8.1.3. Rapid-Acting Insulin Analogues
  • 8.1.4. Recombinant Human Insulin
• 8.2. Peptide Therapeutics
  • 8.2.1. Calcitonin-Based Therapies
  • 8.2.2. Glucagon-Like Peptide-1 Receptor Agonists
  • 8.2.3. Vasopressin Analogs

9. Oral Proteins & Peptides Market, by Formulation

• 9.1. Capsule Formulations
• 9.2. Liquid Formulations
• 9.3. Powder Formulations
• 9.4. Tablet Formulations

10. Oral Proteins & Peptides Market, by Development Stage

• 10.1. Phase I & II Clinical Trials
• 10.2. Phase III Clinical Trials
• 10.3. Post-Market Surveillance
• 10.4. Preclinical Studies

11. Oral Proteins & Peptides Market, by Application

• 11.1. Cancer Treatment
• 11.2. Cardiovascular Diseases
• 11.3. Diabetes Management
• 11.4. Hormonal Disorders

12. Oral Proteins & Peptides Market, by End-User

• 12.1. Home Care Settings
• 12.2. Hospitals & Clinics
• 12.3. Research Laboratories
• 12.4. Specialty Clinics

13. Oral Proteins & Peptides Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Oral Proteins & Peptides Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Oral Proteins & Peptides Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. AbbVie Inc.
  • 16.3.2. Amgen Inc.
  • 16.3.3. Amryt Pharma plc
  • 16.3.4. Astellas Pharma Inc.
  • 16.3.5. AstraZeneca PLC
  • 16.3.6. Biocon Limited
  • 16.3.7. Boehringer Ingelheim International GmbH
  • 16.3.8. Catalent, Inc.
  • 16.3.9. Entera Bio Ltd. by DNA Biomedical Solutions
  • 16.3.10. F. Hoffmann-La Roche AG
  • 16.3.11. Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital
  • 16.3.12. Johnson & Johnson Services, Inc.
  • 16.3.13. Merck KGaA
  • 16.3.14. Novartis AG
  • 16.3.15. Novo Nordisk A/S
  • 16.3.16. Oramed Pharmaceuticals Inc.
  • 16.3.17. PeptiDream Inc.
  • 16.3.18. Pfizer, Inc.
  • 16.3.19. Protagonist Therapeutics, Inc.
  • 16.3.20. Proxima Concepts Limited
  • 16.3.21. Rani Therapeutics, LLC
  • 16.3.22. Sanofi S.A.
  • 16.3.23. Tarsa Therapeutics, Inc.
  • 16.3.24. Teva Pharmaceutical Industries Ltd.
  • 16.3.25. Zealand Pharma A/S

LIST OF FIGURES

• FIGURE 1. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. ORAL PROTEINS & PEPTIDES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. ORAL PROTEINS & PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ORAL PROTEINS & PEPTIDES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COMBINATION INSULIN PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COMBINATION INSULIN PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COMBINATION INSULIN PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COMBINATION INSULIN PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COMBINATION INSULIN PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COMBINATION INSULIN PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LONG-ACTING INSULIN ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LONG-ACTING INSULIN ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LONG-ACTING INSULIN ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LONG-ACTING INSULIN ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LONG-ACTING INSULIN ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LONG-ACTING INSULIN ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RAPID-ACTING INSULIN ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RAPID-ACTING INSULIN ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RAPID-ACTING INSULIN ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RAPID-ACTING INSULIN ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RAPID-ACTING INSULIN ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RAPID-ACTING INSULIN ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RECOMBINANT HUMAN INSULIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RECOMBINANT HUMAN INSULIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RECOMBINANT HUMAN INSULIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RECOMBINANT HUMAN INSULIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RECOMBINANT HUMAN INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RECOMBINANT HUMAN INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN-BASED THERAPIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN-BASED THERAPIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN-BASED THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN-BASED THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN-BASED THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN-BASED THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY VASOPRESSIN ANALOGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY VASOPRESSIN ANALOGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY VASOPRESSIN ANALOGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY VASOPRESSIN ANALOGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY VASOPRESSIN ANALOGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY VASOPRESSIN ANALOGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CAPSULE FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CAPSULE FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CAPSULE FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CAPSULE FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CAPSULE FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CAPSULE FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LIQUID FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LIQUID FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LIQUID FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LIQUID FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POWDER FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POWDER FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POWDER FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POWDER FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POWDER FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POWDER FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY TABLET FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY TABLET FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY TABLET FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY TABLET FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY TABLET FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY TABLET FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE I & II CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE I & II CLINICAL TRIALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE I & II CLINICAL TRIALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE I & II CLINICAL TRIALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE I & II CLINICAL TRIALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE I & II CLINICAL TRIALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRECLINICAL STUDIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRECLINICAL STUDIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRECLINICAL STUDIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRECLINICAL STUDIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRECLINICAL STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRECLINICAL STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CANCER TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CANCER TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CANCER TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CANCER TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 171. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 172. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 173. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 174. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 175. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2024 (USD MILLION)
• TABLE 176. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2025-2032 (USD MILLION)
• TABLE 177. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 178. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2025-2032 (USD MILLION)
• TABLE 179. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 180. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 181. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 182. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
• TABLE 183. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 184. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 185. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 186. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 187. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 190. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 191. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2024 (USD MILLION)
• TABLE 192. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2025-2032 (USD MILLION)
• TABLE 193. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 194. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2025-2032 (USD MILLION)
• TABLE 195. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 196. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 197. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 198. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
• TABLE 199. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 200. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 201. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 202. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 203. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 204. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 205. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 206. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 207. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2024 (USD MILLION)
• TABLE 208. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2025-2032 (USD MILLION)
• TABLE 209. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 210. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2025-2032 (USD MILLION)
• TABLE 211. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 212. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 213. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 214. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
• TABLE 215. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 216. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 217. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 218. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2025-2032 (USD MILLION)
• TABLE 227. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 228. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 229. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 230. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
• TABLE 231. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 232. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 233. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 234. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 235. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 236. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 237. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 238. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 239. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2024 (USD MILLION)
• TABLE 240. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2025-2032 (USD MILLION)
• TABLE 241. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 242. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2025-2032 (USD MILLION)
• TABLE 243. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 244. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 245. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 246. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
• TABLE 247. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 248. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 249. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 250. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 251. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 252. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 253. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 254. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 255. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2024 (USD MILLION)
• TABLE 256. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2025-2032 (USD MILLION)
• TABLE 257. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 258. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2025-2032 (USD MILLION)
• TABLE 259. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 260. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 261. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 262. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
• TABLE 263. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 264. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 265. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 266. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 267. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 268. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 269. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 270. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 271. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2024 (USD MILLION)
• TABLE 272. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2025-2032 (USD MILLION)
• TABLE 273. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 274. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2025-2032 (USD MILLION)
• TABLE 275. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 276. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 277. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 278. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
• TABLE 279. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 280. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 281. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 282. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 283. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 284. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 285. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 286. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 287. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2024 (USD MILLION)
• TABLE 288. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2025-2032 (USD MILLION)
• TABLE 289. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 290. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2025-2032 (USD MILLION)
• TABLE 291. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 292. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 293. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 294. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
• TABLE 295. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 296. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 297. ASIA-PACIFIC ORAL